Chapter 1 Molecular Mechanism of Type IV Collagen-Derived Endogenous Inhibitors of Angiogenesis

Methods in Enzymology

Volumn 444, Issue , 2008, Pages 1-19

  Cooke, Vesselina G ^a   Kalluri, Raghu ^a,b,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ARRESTEN; CANSTATIN; COLLAGEN TYPE 4; GROWTH FACTOR; MATRIGEL; SCLEROPROTEIN; TUMSTATIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ASSAY; CELL MIGRATION; CELL PROLIFERATION; DRUG MECHANISM; ENDOTHELIUM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; COLLAGEN TYPE IV; HUMANS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 55449086566     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(08)02801-2     Document Type: Review

References (48)

1. Akhtar N., Dickerson E.B., and Auerbach R. The sponge/Matrigel angiogenesis assay. Angiogenesis 5 (2002) 75-80
2. Augustin H.G. [Angiogenesis research-quo vadis?]. Ophthalmologe 100 (2003) 104-110
3. Bishop E.T., Bell G.T., Bloor S., Broom I.J., Hendry N.F., and Wheatley D.N. An in vitro model of angiogenesis: Basic features. Angiogenesis 3 (1999) 335-344
4. Bloch W., Forsberg E., Lentini S., Brakebusch C., Martin K., Krell H.W., Weidle U.H., Addicks K., and Fassler R. Beta 1 integrin is essential for teratoma growth and angiogenesis. J. Cell Biol. 139 (1997) 265-278
5. Cao Y. Endogenous angiogenesis inhibitors and their therapeutic implications. Int. J. Biochem. Cell Biol. 33 (2001) 357-369
6. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 9 (2003) 653-660
7. Chen H.C. Boyden chamber assay. Methods Mol. Biol. 294 (2005) 15-22
8. Clark E.A., and Brugge J.S. Integrins and signal transduction pathways: The road taken. Science 268 (1995) 233-239
9. Colorado P.C., Torre A., Kamphaus G., Maeshima Y., Hopfer H., Takahashi K., Volk R., Zamborsky E.D., Herman S., Sarkar P.K., Ericksen M.B., Dhanabal M., et al. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res. 60 (2000) 2520-2526
10. Direcks W.G., van Gelder M.B., Lammertsma A.A., and Molthoff C.F. A new rat model of human breast cancer for evaluating efficacy of new anti-cancer agents in vivo. Cancer Biol. Ther. 3 4 (2008) 7
11. Fadok V.A., Bratton D.L., Rose D.M., Pearson A., Ezekewitz R.A., and Henson P.M. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature 405 (2000) 85-90
12. Folkman J. Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 285 (1971) 1182-1186
13. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1 (1995) 27-31
14. Folkman J., and Shing Y. Angiogenesis. J. Biol. Chem. 267 (1992) 10931-10934
15. Frisch S.M., Vuori K., Ruoslahti E., and Chan-Hui P.Y. Control of adhesion-dependent cell survival by focal adhesion kinase. J. Cell Biol. 134 (1996) 793-799
16. Gagnon E., Cattaruzzi P., Griffith M., Muzakare L., LeFlao K., Faure R., Beliveau R., Hussain S.N., Koutsilieris M., and Doillon C.J. Human vascular endothelial cells with extended life spans: In vitro cell response, protein expression, and angiogenesis. Angiogenesis 5 (2002) 21-33
17. Grant M.A., and Kalluri R. Structural basis for the functions of endogenous angiogenesis inhibitors. Cold Spring Harb. Symp. Quant. Biol. 70 (2005) 399-410
18. Guo W., and Giancotti F.G. Integrin signalling during tumour progression. Nat. Rev. Mol. Cell Biol. 5 (2004) 816-826
19. Han J., Ohno N., Pasco S., Monboisse J.C., Borel J.P., and Kefalides N.A. A cell binding domain from the alpha3 chain of type IV collagen inhibits proliferation of melanoma cells. J. Biol. Chem. 272 (1997) 20395-20401
20. He G.A., Luo J.X., Zhang T.Y., Wang F.Y., and Li R.F. Canstatin-N fragment inhibits in vitro endothelial cell proliferation and suppresses in vivo tumor growth. Biochem. Biophys. Res. Commun. 312 (2003) 801-805
21. Hou W.H., Wang T.Y., Yuan B.M., Chai Y.R., Jia Y.L., Tian F., Wang J.M., and Xue L.X. Recombinant mouse canstatin inhibits chicken embryo chorioallantoic membrane angiogenesis and endothelial cell proliferation. Acta Biochim. Biophys. Sin. (Shanghai) 36 (2004) 845-850
22. 3H-thymidine is a defective tool with which to measure rates of DNA synthesis. FASEB J. 16 (2002) 1456-1457
23. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., Bodmer J.L., Schroter M., Burns K., Mattmann C., Rimoldi D., French L.E., et al. Inhibition of death receptor signals by cellular FLIP. Nature 388 (1997) 190-195
24. Kamphaus G.D., Colorado P.C., Panka D.J., Hopfer H., Ramchandran R., Torre A., Maeshima Y., Mier J.W., Sukhatme V.P., and Kalluri R. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J. Biol. Chem. 275 (2000) 1209-1215
25. Kawaguchi T., Yamashita Y., Kanamori M., Endersby R., Bankiewicz K.S., Baker S.J., Bergers G., and Pieper R.O. The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. Cancer Res. 66 (2006) 11331-11340
26. Kuhn K., Wiedemann H., Timpl R., Risteli J., Dieringer H., Voss T., and Glanville R.W. Macromolecular structure of basement membrane collagens. FEBS Lett. 125 (1981) 123-128
27. Lawley T.J., and Kubota Y. Induction of morphologic differentiation of endothelial cells in culture. J. Invest. Dermatol. 93 (1989) 59S-61S
28. Maeshima Y., Colorado P.C., and Kalluri R. Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J. Biol. Chem. 275 (2000) 23745-23750
29. Maeshima Y., Colorado P.C., Torre A., Holthaus K.A., Grunkemeyer J.A., Ericksen M.B., Hopfer H., Xiao Y., Stillman I.E., and Kalluri R. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J. Biol. Chem. 275 (2000) 21340-21348
30. Maeshima Y., Manfredi M., Reimer C., Holthaus K.A., Hopfer H., Chandamuri B.R., Kharbanda S., and Kalluri R. Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J. Biol. Chem. 276 (2001) 15240-15248
31. Maeshima Y., Sudhakar A., Lively J.C., Ueki K., Kharbanda S., Kahn C.R., Sonenberg N., Hynes R.O., and Kalluri R. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 295 (2002) 140-143
32. Magnon C., Galaup A., Mullan B., Rouffiac V., Bouquet C., Bidart J.M., Griscelli F., Opolon P., and Perricaudet M. Canstatin acts on endothelial and tumor cells via mitochondrial damage initiated through interaction with alphavbeta3 and alphavbeta5 integrins. Cancer Res. 65 (2005) 4353-4361
33. Montesano R., Pepper M.S., and Orci L. Paracrine induction of angiogenesis in vitro by Swiss 3T3 fibroblasts. J. Cell Sci. 105 Pt 4 (1993) 1013-1024
34. Mundel T.M., and Kalluri R. Type IV collagen-derived angiogenesis inhibitors. Microvasc. Res. 74 (2007) 85-89
35. Nagata S. Fas-mediated apoptosis. Adv. Exp. Med. Biol. 406 (1996) 119-124
36. Nyberg P., Xie L., and Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res. 65 (2005) 3967-3979
37. Panka D.J., and Mier J.W. Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. J. Biol. Chem. 278 (2003) 37632-37636
38. Semenza G.L. HIF-1 and human disease: One highly involved factor. Genes Dev. 14 (2000) 1983-1991
39. Senger D.R., Claffey K.P., Benes J.E., Perruzzi C.A., Sergiou A.P., and Detmar M. Angiogenesis promoted by vascular endothelial growth factor: Regulation through alpha1beta1 and alpha2beta1 integrins. Proc. Natl. Acad. Sci. USA 94 (1997) 13612-13617
40. Shahan T.A., Ziaie Z., Pasco S., Fawzi A., Bellon G., Monboisse J.C., and Kefalides N.A. Identification of CD47/integrin-associated protein and alpha(v)beta3 as two receptors for the alpha3(IV) chain of type IV collagen on tumor cells. Cancer Res. 59 (1999) 4584-4590
41. Sidky Y.A., and Borden E.C. Inhibition of angiogenesis by interferons: Effects on tumor- and lymphocyte-induced vascular responses. Cancer Res. 47 (1987) 5155-5161
42. Staton C.A., Stribbling S.M., Tazzyman S., Hughes R., Brown N.J., and Lewis C.E. Current methods for assaying angiogenesis in vitro and in vivo. Int. J. Exp. Pathol. 85 (2004) 233-248
43. Sudhakar A., Nyberg P., Keshamouni V.G., Mannam A.P., Li J., Sugimoto H., Cosgrove D., and Kalluri R. Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrin. J. Clin. Invest. 115 (2005) 2801-2810
44. Sudhakar A., Sugimoto H., Yang C., Lively J., Zeisberg M., and Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc. Natl. Acad. Sci. USA 100 (2003) 4766-4771
45. Sund M., Hamano Y., Sugimoto H., Sudhakar A., Soubasakos M., Yerramalla U., Benjamin L.E., Lawler J., Kieran M., Shah A., and Kalluri R. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc. Natl. Acad. Sci. USA 102 (2005) 2934-2939
46. Teodoro J.G., Parker A.E., Zhu X., and Green M.R. p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science 313 (2006) 968-971
47. Timpl R., Wiedemann H., van Delden V., Furthmayr H., and Kuhn K. A network model for the organization of type IV collagen molecules in basement membranes. Eur. J. Biochem. 120 (1981) 203-211
48. van Engeland M., Nieland L.J., Ramaekers F.C., Schutte B., and Reutelingsperger C.P. Annexin V-affinity assay: A review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 31 (1998) 1-9